EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische Studie

Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease

Ashish O Gupta, Akshay Sharma iD, Haydar Frangoul iD, Julie Kanter, Markus Y Mapara, Jignesh Dalal, Asif Alavi, Jennifer J Jaroscak, Ernesto Ayala, John F DiPersio iD, Edward D Ziga, Mary Eapen iD und 15 weitere

New England Journal of Medicine · 07.05.2026 · 394 (18) · 1824-1835

DOI: 10.1056/nejmoa2504835 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 07.05.2026. Verfasst von Ashish O Gupta und 26 weiteren Autor:innen. Beteiligte Einrichtung: University of Minnesota, Minneapolis. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Fetal Hemoglobin, gamma-Globins, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Beam Therapeutics Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellFetal Hemoglobingamma-GlobinsHematopoietic Stem Cell TransplantationHemoglobin, SicklePromoter Regions, GeneticGene Therapy AgentsAdolescentAdultFemaleHumansMaleYoung AdultGene EditingRepressor ProteinsMyeloablative AgonistsBusulfanTransplantation ConditioningVaso-Occlusive CrisesSeverity of Illness IndexFollow-Up StudiesGene Expression RegulationTreatment Outcome

Substanzen

Fetal Hemoglobingamma-GlobinsHemoglobin, SickleBCL11A protein, humanRepressor ProteinsMyeloablative AgonistsBusulfan

Autor:innen und Institutionen

  • University of Minnesota, Minneapolis.
  • St. Jude Children's Research Hospital, Memphis, TN.
  • Sarah Cannon Research Institute, Nashville.
  • TriStar Centennial Children's Hospital, Nashville.
  • University of Alabama at Birmingham, Birmingham.
  • Columbia University Medical Center, New York.

ORCID-Profile: Akshay Sharma, Haydar Frangoul, John F DiPersio, Mary Eapen, Alexis A Thompson

Förderung

  • Beam Therapeutics Inc

Zitieren

APA

Gupta, A. O., Sharma, A., Frangoul, H., Kanter, J., Mapara, M. Y., Dalal, J., Alavi, A., Jaroscak, J. J., Ayala, E., DiPersio, J. F., Ziga, E. D., Eapen, M., Rifkin-Zenenberg, S., Minella, A. C., Chen, Y., Chesler, S., Ambati, S., Bowman, T. S., Habtemariam, B., …, & BEACON Investigators (2026). Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease. New England Journal of Medicine, 394(18), 1824-1835. https://doi.org/10.1056/nejmoa2504835

Vancouver

Gupta AO, Sharma A, Frangoul H, Kanter J, Mapara MY, Dalal J, et al. Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease. New England Journal of Medicine. 2026;394(18):1824-1835. doi:10.1056/nejmoa2504835

BibTeX
@article{Gupta2026,
  author = {Gupta, Ashish O and Sharma, Akshay and Frangoul, Haydar and Kanter, Julie and Mapara, Markus Y and Dalal, Jignesh and Alavi, Asif and Jaroscak, Jennifer J and Ayala, Ernesto and DiPersio, John F and Ziga, Edward D and Eapen, Mary and Rifkin-Zenenberg, Stacey and Minella, Alex C and Chen, Yinzhong and Chesler, Sarah and Ambati, Srikanth and Bowman, Thomas S and Habtemariam, Bahru and Joseney-Antoine, Marcelyne and Chockalingam, Priya S and Lin, Ling and Goyal, Sunita and Simon, Amy and Thompson, Alexis A and Heeney, Matthew M and BEACON Investigators, BEACON Investigators},
  title = {Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {18},
  pages = {1824--1835},
  doi = {10.1056/nejmoa2504835}
}
Kostenlos starten →